Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diacylglycerol acyltransferase-2 (DGAT2) is an integral membrane protein and a key enzyme in lipid metabolism. It catalyzes the final step in the synthesis of triacylglycerol (TG), a major form of energy storage in eukaryotic cells, by covalently attaching a fatty acyl-CoA to diacylglycerol. This reaction is essential for lipid droplet formation and energy homeostasis. Abnormal expression or activity has been linked to metabolic disorders such as obesity, hepatic steatosis (fatty liver disease), insulin resistance, and cardiovascular diseases due to altered lipid accumulation or mobilization.
Inhibition of diacylglycerol acyltransferase 2, leading to reduced triglyceride synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diacylglycerol Acyltransferase 2 (DGAT2).